Perfuse Therapeutics has reported 24-week data from its first-in-human, multi-centre Phase I/IIa trial of the PER-001 intravitreal implant for individuals with glaucoma. The trial of PER-001 is ...

"We are thrilled to welcome Paul Sowyrda and Steven Schiffman to our Board ... In-Office MIGS: A Paradigm Shift in Ophthalmology Hexiris is pioneering a new generation of glaucoma surgery. Unlike ...